MN-ENTRUST-DATACARD
11.2.2020 15:02:10 CET | Business Wire | Press release
Entrust Datacard , a leading provider of trusted identity and secure issuance technology solutions, today announced two new high-assurance offerings for the company’s unified authentication management platform: Passwordless Single Sign On (SSO) Authentication to improve workforce security and productivity, and Identity Proofing with fully digital identity verification for accelerated customer acquisition and onboarding.
As digital transformation, cloud deployments and mobile initiatives make communication, data storage and remote workstyles dramatically simpler, employees and customers around the world expect security features to follow suit, without compromising user experiences. The latest Entrust Datacard authentication solutions both increase high-assurance security and simplify user experiences.
Entrust Datacard’s Passwordless SSO Authentication solution turns employee smartphones into biometrics-protected virtual smart cards that allow instant proximity-based login to both workstations and applications. The solution creates a frictionless authentication experience, eliminating passwords and putting an end to the risk of bad actors stealing user credentials and compromising critical information.
Taking passwordless login to an SSO experience removes the friction of individual registrations and logins for each device, allowing employees to work across devices and applications – cloud-based and on-premises. The solution improves workforce productivity by enabling employees to securely conduct their work activities – email signing, file encryption, document signing, and more – from their office or remote location without the need to upgrade their hardware or operating system.
Entrust Datacard’s new Identity Proofing solution lets banks, hospitals, government agencies and other customer and citizen-facing organizations offer customers a simple, seamless onboarding experience, either inside or outside physical locations. With Identity Proofing, customers use their smartphones or a kiosk to capture their images and scan government-issued identity documents – such as a driver’s license, passport or national ID card – for fast, AI-based authentication and verification.
Once authenticated and verified, the user can complete their account application securely. This minimizes abandoned account applications, cuts onboarding time from multiple days to minutes and has the potential to reduce an organization’s onboarding costs from hundreds of dollars per account to single digits. The fully digital Identity Proofing solution supports compliance with regional regulations, such as Know Your Customer (KYC) and Anti-Money Laundering (AML) in the United States, and PSD2 in Europe.
“Digital transformation is driving the demand for authentication that is both incredibly easy and highly secure – features once thought incompatible,” said James LaPalme, VP and GM of Authentication at Entrust Datacard. “By delivering passwordless SSO authentication, enterprises can eliminate passwords and transform the employee experience, while increasing privacy and data security. Similarly, our Identity Proofing solution creates a truly digital customer onboarding experience, streamlining and automating what has until now been a costly, manual and less-secure process behind the scenes.”
To learn more about the Entrust Datacard Passwordless SSO Authentication and Identity Proofing solutions visit RSA Conference booth #S-2139 from February 24-28 at the Moscone Center in San Francisco or head to https://www.entrustdatacard.com/products/categories/authentication .
About Entrust Datacard Corporation
Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure issuance technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates, hardware security modules and secure communications. With more than 2,800 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
